NM X1
Alternative Names: NM-X1Latest Information Update: 28 Aug 2026
At a glance
- Originator NovoMedix
- Class Antineoplastics; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Interleukin 11 inhibitors; MTOR protein inhibitors; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Yes - Sarcoma; Breast cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Lung cancer; Pancreatic cancer; Sarcoma; Triple negative breast cancer
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (PO)
- 28 Aug 2026 No recent reports of development identified for preclinical development in Lung-cancer in USA (PO)
- 28 Aug 2026 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (PO)